1 Guidance

1 Guidance

This guidance replaces previous guidance on hysteroscopic sterilisation by tubal cannulation and placement of intrafallopian implants (interventional procedure guidance 44).

1.1 Current evidence on the safety and efficacy of hysteroscopic sterilisation by tubal cannulation and placement of intrafallopian implants is adequate to support the use of this procedure provided that normal arrangements are in place for clinical governance and audit.

1.2 During the consent process clinicians wishing to undertake hysteroscopic sterilisation by tubal cannulation and placement of intrafallopian implants should take the following action.

  • Ensure that patients understand that additional contraception must be used until appropriate imaging has been done; and that there is a small risk of pregnancy in the longer term after any form of tubal occlusion procedure. Patients should be provided with clear written information. In addition, the use of NICE's information for patients ('Understanding NICE guidance') is recommended.

  • National Institute for Health and Care Excellence (NICE) accreditation logo